Linaglip-M 2.5/500

Generic

Linagliptin + Metformin Hydrochloride

Indications

Linagliptin is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults.

Pharmacology

Linagliptin is shown to move forward glycemic control in patients with sort 2 diabetes mellitus. Linagliptin is an inhibitor of DPP-4 (dipeptidyl peptidase-4), a protein that debases the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose subordinate insulinotropic polypeptide). Hence, Linagliptin increments the concentrations of dynamic incretin hormones, invigorating the discharge of affront from pancreatic beta (β) cells in a glucose-dependent way and diminishing the emission of glucagon from pancreatic alpha (α) cells within the circulation.

Dosage & Administration

Linagliptin & Metformin immediate release tablet: The dosage of Linagliptin & Metformin should be individualized on the basis of both effectiveness and tolerability. Maximum recommended dose of 2.5 mg Linagliptin and 1000 mg Metformin Hydrochloride twice daily with meals. Dose escalation should be gradual to reduce the gastrointestinal (GI) side effects associated with Metformin Hydrochloride use.

Recommended starting dose: In patients currently not treated with Metformin Hydrochloride, initiate treatment with 2.5 mg Linagliptin and 500 mg Metformin Hydrochloride twice daily.In patients already treated with Metformin Hydrochloride, start with 2.5 mg Linagliptin and the current dose of Metformin Hydrochloride twice daily.

Patients already treated with Linagliptin and Metformin Hydrochloride, individual components may be switched to this combination containing the same doses of each component.


Linagliptin & Metformin extend release tablet: The dosage of this combination should be individualized on the basis of both effectiveness and tolerability, while not exceeding the maximum recommended total daily dose of Linagliptin 5 mg and Metformin Hydrochloride 2000 mg. this combination should be given once daily with a meal.

Recommended starting dose: In patients currently not treated with metformin, initiate this combination treatment with 5 mg Linagliptin/1000 mg Metformin Hydrochloride extended-release once daily with a meal.

In patients already treated with Metformin, start this combination with 5 mg of Linagliptin total daily dose and a similar total daily dose of Metformin once daily with a meal.

In patients already treated with Linagliptin & Metformin immediate release tablet, switch to extend release tablet containing 5 mg of Linagliptin total daily dose and a similar total daily dose of Metformin once daily with a meal.

5 mg Linagliptin & 1000 mg Metformin Hydrochloride extended-release tablet should be taken as a single tablet once daily. Patients using 2.5 mg Linagliptin & 1000 mg Metformin extended release tablets should take two tablets together once daily.

Interaction

Linagliptin could be a frail competitive and powerless to direct mechanism-based inhibitor of CYP isozyme CYP3A4 but does not hinder other CYP isozymes. The chance for clinically significant intuition by other restorative items on linagliptin is moo and in clinical considers linagliptin had no clinically significant impact on the pharmacokinetics of metformin, glyburide, simvastatin, warfarin, digoxin, or verbal contraceptives.

Contraindications

Hypersensitivity to the active substance or any excipient.

Side Effect

When metformin and sulfonylurea are used together, hypoglycemia, nasopharyngitis, cough, and pancreatitis might occur.

Pregnancy & Lactation

Pregnancy category B. There are no satisfactory and well-controlled ponders in pregnant ladies. So, Linagliptin tablets ought to be utilized amid pregnancy as it were in the case clearly required. It isn't known whether Linagliptin passes into breast drain or not.

Precautions & Warnings

Hypersensitivity to the active ingredient or any excipient.

Therapeutic Class

Dipeptidyl Peptidase-4 (DPP-4) inhibitor

Storage Conditions

Store in a cool and dry place, protected from light.

Pharmaceutical Name

Aristopharma Ltd.